• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    AstraZeneca's Q1 2025 Financial Results

    4/29/25 2:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AZN alert in real time by email

    Growth momentum and pipeline delivery set AstraZeneca on a strong trajectory towards 2030 ambition

    AstraZeneca:

    Revenue and EPS summary

     

    Q1 2025

    % Change

     

     

     

    $m

    Actual

    CER1

     

     

     

    - Product Sales

    12,875

    6

    9

     

     

     

    - Alliance Revenue

    639

    40

    42

     

     

     

    Product Revenue2

    13,514

    7

    10

     

     

     

    Collaboration Revenue

    74

    64

    64

     

     

     

    Total Revenue

    13,588

    7

    10

     

     

     

    Reported EPS ($)

    1.88

    34

    32

     

     

     

    Core3 EPS ($)

    2.49

    21

    21

     

     

     

    Key performance elements for Q1 2025

    (Growth numbers at constant exchange rates)

    • Total Revenue up 10% to $13,588m, driven by double-digit growth in Oncology and BioPharmaceuticals
    • Growth in Total Revenue across all major geographic regions
    • Core Operating profit increased 12%
    • Core Tax rate of 16% in the quarter due to timing of settlements. Expectations for the full year Core tax rate are unchanged at 18-22%
    • Core EPS increased 21% to $2.49
    • Five positive Phase III readouts and 13 approvals in major regions since the prior results

    Pascal Soriot, Chief Executive Officer, AstraZeneca, said:

    "Our strong growth momentum has continued into 2025 and we have now entered an unprecedented catalyst-rich period for our company.

    Already this year we have announced five positive Phase III study readouts, including most recently the highly anticipated DESTINY-Breast09 for Enhertu, as well as SERENA-6 for camizestrant and MATTERHORN for Imfinzi; the latter two of these will feature in the ASCO 2025 plenary sessions, reflecting the significance of these data to the oncology community.

    Our company is firmly committed to investing and growing in the US and we continue to benefit from our broad-based source of revenue and global manufacturing footprint, including eleven production sites in the US covering small molecules, biologics as well as cell therapy. Additionally, we have even greater US investment in manufacturing and R&D planned, leveraging our two large R&D sites in Gaithersburg MD and Cambridge MA.

    Overall, we are making excellent progress toward our ambition of eighty billion dollars in Total Revenue by 2030."

    See Table 1 for details of clinical trial results since the prior earnings announcement, including DESTINY-Breast09, MATTERHORN, and SERENA-6.

    See Note 4 for the locations of the eleven US manufacturing sites.

    Guidance

    AstraZeneca reiterates its Total Revenue and Core EPS guidance5 for FY 2025 at CER, based on the average foreign exchange rates through 2024.

    Total Revenue is expected to increase by a high single-digit percentage

    Core EPS is expected to increase by a low double-digit percentage

    – The Core Tax rate is expected to be between 18-22%

    – If foreign exchange rates for April 2025 to December 2025 were to remain at the average rates seen in March 2025, it is anticipated that compared to the performance at CER, FY 2025 Total Revenue would incur a low single-digit percentage adverse impact (unchanged from prior guidance), and Core EPS would incur a low single-digit percentage adverse impact (previously mid single-digit).

    Results highlights

    Table 1. Milestones achieved since the prior results announcement

    Phase III and other registrational data readouts

    Medicine

    Trial

    Indication

    Event

    Enhertu

    DESTINY-Gastric04

    HER2-positive gastric/GEJ cancer (2nd-line)

    Primary endpoint met

    Enhertu

    DESTINY-Breast09

    HER2-positive metastatic breast cancer (1st line)

    Primary endpoint met for combination arm

    Imfinzi

    MATTERHORN

    Resectable gastric/GEJ cancer

    Primary endpoint met

    camizestrant

    SERENA-6

    HR+ HER2- metastatic breast cancer (1st line switch on emergence of ESR1m)

    Primary endpoint met

    eneboparatide

    CALYPSO

    Chronic hypoparathyroidism

    Primary endpoint met, trial continues to 52 weeks

    Regulatory approvals

    Medicine

    Trial

    Indication

    Region

    Calquence

    ACE-LY-004

    Relapsed/refractory MCL

    EU

    Calquence

    ChangE

    CLL/SLL

    CN

    Datroway

    TROPION-Breast01

    HR+ HER2- breast cancer (2nd-line)

    EU

    Enhertu

    DESTINY-Breast06

    HER2-low and -ultralow HR+ breast cancer (2nd-line+)

    EU

    Imfinzi

    AEGEAN

    Resectable early-stage (IIA-IIIB) NSCLC

    EU, CN

    Imfinzi

    NIAGARA

    MIBC

    US

    Imfinzi ± Imjudo

    ADRIATIC

    SCLC (limited-stage)

    EU, JP

    Truqap

    CAPItello-291

    Biomarker-altered HR+ HER2- metastatic breast cancer

    CN

    Wainzua

    NEURO-TTRansform

    ATTRv-PN

    EU

    Beyonttra (acoramidis)

    NCT04622046

    ATTR-CM

    JP

    Ultomiris

    CHAMPION-MG

    gMG

    CN

    Regulatory submissions or acceptances* in major regions

    Medicine

    Trial

    Indication

    Region

    Enhertu

    DESTINY-Breast06

    HER2-low and -ultralow HR+ breast cancer (2nd-line+)

    CN

    Imfinzi

    PACIFIC-5

    Locally advanced NSCLC

    CN

    Imfinzi + Imjudo

    HIMALAYA

    Unresectable HCC

    CN

    Imfinzi

    HIMALAYA

    Unresectable HCC

    CN

    Imfinzi

    DUO-E

    Primary advanced or recurrent endometrial cancer with mismatch repair deficiency

    CN

    Fasenra

    MANDARA

    EGPA

    CN

    Tezspire

    WAYPOINT

    CRSwNP

    US, EU, JP, CN

    Koselugo

    KOMET

    NF1-PN (adults)

    US, CN

    * US, EU and China regulatory submissions denotes filing acceptance

    Other pipeline updates

    For recent trial starts and anticipated timings of key trial readouts, please refer to the Clinical Trials Appendix, available on www.astrazeneca.com/investor-relations.html.

    Table 2: Key elements of financial performance in Q1 2025

    Item

    Reported

    Change

    Core

    Change

     

     

    $m

    Act

    CER

    $m

    Act

    CER

     

    Product Revenue

    13,514

    7

    10

    13,514

    7

    10

    ■ See Tables 3 and 24 for medicine details of Product Revenue, Alliance Revenue and Product Sales

    Collaboration Revenue

    74

    64

    64

    74

    64

    64

    ■ See Table 4 for details of Collaboration Revenue

    Total Revenue

    13,588

    7

    10

    13,588

    7

    10

    ■ See Tables 5 and 6 for Total Revenue by Therapy Area and by region

    Gross Margin (%)

    84

    +1pp

    -

    84

    +1pp

    -

    + Fluctuations in foreign exchange rates

    − Pricing adjustments, for example to sales reimbursed by the Medicare Part D programme in the US

    ■ See 'Reporting changes' below for the definition of Gross Margin6

    ■ Variations in Gross Margin can be expected between periods, due to fluctuations in foreign exchange rates, product seasonality, Collaboration Revenue, and other effects

    R&D expense

    3,159

    13

    15

    3,088

    14

    16

    ■ Core R&D: 23% of Total Revenue

    + Positive data read-outs for high value pipeline opportunities that have ungated late-stage trials

    + Investment in platforms, new technology and capabilities to enhance R&D capabilities

    SG&A expense

    4,492

    -

    3

    3,457

    1

    4

    ■ Core SG&A: 25% of Total Revenue

    Other operating income and expense7

    113

    71

    71

    115

    79

    78

    + Upfront receipt on a divestment

    Operating Margin (%)

    27

    +2pp

    +2pp

    35

    +1pp

    -

     

    Net finance expense

    265

    (12)

    (11)

    215

    (12)

    (11)

    + Debt issued in 2024 at higher interest rates

    − Adjustment relating to tax settlements (see below)

    Tax rate (%)

    14

    -8pp

    -8pp

    16

    -6pp

    -6pp

    − Updates to estimates of prior period tax liabilities following settlements with tax authorities

    EPS ($)

    1.88

    34

    32

    2.49

    21

    21

     

    For monetary values the unit of change is percent; for Gross Margin, Operating Margin and Tax rate the unit of change is percentage points.

    In the expense commentary above, the plus and minus bullets denote the directional impact of the item being discussed, e.g. a '+' symbol beside an R&D expense comment indicates that the item resulted in an increase in the R&D spend relative to the prior year.

    China

    In April 2025, there are following developments in relation to the China investigations:

    First, in relation to the illegal drug importation allegations, AstraZeneca received an Appraisal Opinion from the Shenzhen City Customs Office regarding suspected unpaid importation taxes amounting to $1.6 million. To the best of AstraZeneca's knowledge, the importation taxes referred to in the Appraisal Opinion relate to Enhertu. A fine of between one and five times the amount of unpaid importation taxes may also be levied if AstraZeneca is found liable.

    Second, in relation to the personal information infringement allegation, AstraZeneca received a Notice of Transfer to the Prosecutor from the Shenzhen Bao'an District Public Security Bureau (the 'PSB') regarding suspected unlawful collection of personal information. The Company has been informed that there was no illegal gain to the Company resulting from personal information infringement.

    AstraZeneca continues to fully cooperate with the Chinese authorities.

    Corporate and business development

    FibroGen

    In February 2025, FibroGen announced the sale of FibroGen China to AstraZeneca.

    Under the terms of the agreement, FibroGen will receive an enterprise value of $85m plus FibroGen net cash held in China at closing, estimated at the date of signing to be approximately $75m, totalling approximately $160m. The transaction is expected to close by mid-2025, pending customary closing conditions, including regulatory review in China.

    Upon closing, AstraZeneca will obtain all rights to roxadustat in China, including manufacturing in China.

    EsoBiotec

    In March 2025, AstraZeneca entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform could offer many more patients access to transformative cell therapy treatments delivered in minutes rather than the current process which takes weeks.

    AstraZeneca will acquire all outstanding equity of EsoBiotec for a total consideration of up to $1bn, on a cash and debt-free basis. This will include an initial payment of $425m on deal closing, and up to $575m in contingent consideration based on development and regulatory milestones. The transaction is expected to close in the second quarter of 2025, subject to customary closing conditions and regulatory clearances.

    Alteogen Inc

    In March 2025, AstraZeneca and Alteogen Inc. entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme™ platform technology. Under the terms of the agreement, AstraZeneca has acquired worldwide rights to use ALT-B4 to develop and commercialise subcutaneous formulations of several oncology assets. Alteogen will be responsible for clinical and commercial supply of ALT-B4 to AstraZeneca. AstraZeneca has made an upfront payment to Alteogen and may make additional payments, conditional on achievement of specific development, regulatory and sales-related milestones. Additionally, Alteogen will receive royalties on the sales of the commercialised products.

    Beijing R&D centre

    In March 2025, AstraZeneca announced it will establish its sixth global strategic R&D centre, to be located in Beijing, China. It will be AstraZeneca's second R&D centre in China, following the opening of the Shanghai R&D centre, and will advance early-stage research and clinical development, enabled by a state-of-the-art artificial intelligence and data science laboratory. The new R&D centre will be located near leading biotech companies, research hospitals, and the National Medical Products Administration in the Beijing International Pharmaceutical Innovation Park (BioPark).

    Harbour BioMed

    In March 2025, AstraZeneca executed a global strategic collaboration with Harbour BioMed to discover and develop next-generation multi-specific antibodies for immunology, oncology and beyond. The strategic collaboration includes an option to license multiple programs utilizing Harbour BioMed's proprietary fully human antibody technology platform in multiple therapeutic areas, together with an equity investment in Harbour BioMed, which closed in April 2025. Upfront payments for the collaboration and equity investment total $175m. AstraZeneca may incur additional fees and contingent milestones for each program it elects to license, along with tiered royalties on future net sales.

    BioKangtai

    In March 2025, BioKangtai and AstraZeneca entered into a strategic partnership to establish a joint venture that focus on researching, developing, and producing innovative vaccines.

    The joint venture will serve as AstraZeneca's first and only vaccine production hub in China, with a registered capital of RMB 345m (approx. $50m) and a total investment of approx. $400m (RMB 2.76bn). BioKangtai and AstraZeneca will each hold 50% equity in the venture.

    Syneron Bio

    In March 2025, AstraZeneca executed a strategic collaboration with Syneron Bio to develop potential first-in-class macrocyclic peptides for the treatment of chronic diseases. Under this collaboration, AstraZeneca will gain access to Syneron Bio's innovative macrocyclic peptide drug research and development platform to support research programmes exploring possible future treatments of chronic diseases, including rare, autoimmune, and metabolic disease. AstraZeneca will pay an upfront payment of $55m, with option exercise fees and contingent milestones of over $3bn if all programs are optioned, along with tiered royalties on future net sales. AstraZeneca will also make an equity investment in Syneron Bio.

    Tempus AI and Pathos AI

    In April 2025, AstraZeneca, Tempus AI, Inc. (Tempus) and Pathos AI, Inc. (Pathos) entered into a series of agreements regarding the development of a foundational large multimodal model in the field of oncology. The model will be used to gather biological and clinical insights, discover novel drug targets, and develop therapeutics. AstraZeneca will pay Tempus a fee, and a syndicate of investors, including AstraZeneca, will contemporaneously execute a stock purchase agreement with Pathos.

    Sustainability highlights

    In preparation for new reporting regulations, AstraZeneca combined its 2024 sustainability and annual reporting into one integrated publication. Details of performance against targets can be found in the 2024 Sustainability Data Annex.

    AstraZeneca published its first Taskforce on Nature-related Financial Disclosures report, and its Sustainable use and sourcing of raw materials report.

    Reporting calendar

    The Company intends to publish its H1 and Q2 2025 results on 29 July 2025.

    Conference call

    A conference call and webcast for investors and analysts will begin today, 29 April 2025, at 11:45 UK time. Details can be accessed via astrazeneca.com.

    Reporting changes

    Product Revenue

    Effective 1 January 2025, the Group has updated the presentation of Total Revenue on the face of the Statement of Comprehensive Income to include a new subtotal 'Product Revenue' representing the summation of Product Sales and Alliance Revenue.

    Product Revenue and Collaboration Revenue form Total Revenue.

    Product Sales and Alliance Revenue will continue to be presented separately, with the new subtotal providing additional aggregation of revenue types with similar characteristics, reflecting the growing importance of Alliance Revenue.

    Full descriptions of Product Sales, Alliance Revenue and Collaboration Revenue are included from page 152 of the Group's Annual Report and Form 20-F Information 2024.

    Gross Margin

    Effective 1 January 2025, the Group has replaced the measure of 'Product Sales Gross Margin' with the measure of 'Gross Margin'. Previously, the measure excluded margin related to Alliance Revenue and Collaboration Revenue. The new measure is calculated using Gross profit as a percentage of Total Revenue, thereby encompassing all revenue categories, and is intended to provide a more comprehensive measure of total performance.

    Notes

    1. Constant exchange rates. The differences between Actual Change and CER Change are due to foreign exchange movements between periods in 2025 vs. 2024. CER financial measures are not accounted for according to generally accepted accounting principles (GAAP) because they remove the effects of currency movements from Reported results.
    2. Effective Jan 1 2025, the Group has updated its presentation of Total Revenue, adding a new subtotal of Product Revenue, the sum of Product Sales and Alliance revenue. For further details, see Note 1: 'Basis of preparation and accounting policy' in the Notes to the Interim Financial Statements.
    3. Core financial measures are adjusted to exclude certain items. The differences between Reported and Core measures are primarily due to costs relating to the amortisation of intangibles, impairments, legal settlements and restructuring charges. A full reconciliation between Reported EPS and Core EPS is provided in Table 9 in the Financial Performance section of this document.
    4. The eleven manufacturing sites in the US (or territories of the US) are:

      - Bogart, GA

      - Coppell, TX

      - Frederick, MD

      - Mt Vernon, IN

      - Newark, DE

      - Philadelphia, PA

      - Puerto Rico

      - Redwood City, CA

      - Rockville, MD *

      - Santa Monica, CA

      - Tarzana, CA

    * Opens in May 2025

    5. The Company is unable to provide guidance on a Reported basis because it cannot reliably forecast material elements of the Reported results, including any fair value adjustments arising on acquisition-related liabilities, intangible asset impairment charges and legal settlement provisions. Please refer to the cautionary statements section regarding forward-looking statements at the end of this announcement.

    6. Effective Jan 1 2025, the Group has updated its presentation of Gross Margin. For further details, see Note 1: 'Basis of preparation and accounting policy' in the Notes to the Interim Financial Statements

    7. Income from disposals of assets and businesses, where the Group does not retain a significant ongoing economic interest, is recorded in Other operating income and expense in the Group's financial statements.

    To read AstraZeneca's Q1 2025 Financial Results press release in full click here.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250428918895/en/

    Global Media Relations team

    [email protected]

    +44 (0)1223 344 800

    Get the next $AZN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AZN

    DatePrice TargetRatingAnalyst
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    2/13/2025Neutral → Buy
    UBS
    2/12/2025Overweight
    Morgan Stanley
    11/20/2024Sell → Neutral
    UBS
    11/6/2024Sell → Hold
    Deutsche Bank
    9/13/2024Hold → Sell
    Deutsche Bank
    5/30/2024$97.00Buy
    Goldman
    4/16/2024Sell → Hold
    Deutsche Bank
    More analyst ratings

    $AZN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma

      AIRSUPRA demonstrated a 47% reduction in the risk of severe exacerbations in mild asthma compared with albuterol alone Full results published in the New England Journal of Medicine and presented at ATS 2025 International Conference Positive full results from the BATURA Phase IIIb trial showed AstraZeneca's anti-inflammatory reliever rescue therapy, AIRSUPRA (albuterol/budesonide), demonstrated statistically significant and clinically meaningful improvements in all primary and secondary endpoints compared to albuterol in patients with mild asthma.1,2 These data were published in the New England Journal of Medicine and presented today at the American Thoracic Society (ATS) 2025 Internationa

      5/19/25 12:34:00 PM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025

      New data for AIRSUPRA and BREZTRI highlight progress in advancing asthma and COPD care globally AstraZeneca will present the latest clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Francisco, CA from May 16 to 21, 2025. With more than 75 abstracts, including eight late-breakers, the Company continues to drive innovation and address unmet needs in care across all severities of asthma, chronic obstructive pulmonary disease (COPD), eosinophilic granulomatosis with polyangiitis (EGPA) and other chronic inflammatory diseases. Ruud Dobber, Executive Vice President an

      5/13/25 7:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial

      Patients lived significantly longer without high-risk disease recurrence or progression after one year of IMFINZI treatment plus Bacillus Calmette-Guérin (BCG) induction and maintenance therapy vs. BCG alone Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with AstraZeneca's IMFINZI® (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) compared to BCG induction and maintenance therapy alone.​ The trial was not statistically powered to formally test ov

      5/9/25 7:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Exane BNP Paribas initiated coverage on AstraZeneca with a new price target

      Exane BNP Paribas initiated coverage of AstraZeneca with a rating of Outperform and set a new price target of $75.00

      4/15/25 12:40:56 PM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AstraZeneca upgraded by UBS

      UBS upgraded AstraZeneca from Neutral to Buy

      2/13/25 8:39:12 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on AstraZeneca

      Morgan Stanley initiated coverage of AstraZeneca with a rating of Overweight

      2/12/25 6:59:42 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    SEC Filings

    See more
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      5/20/25 7:20:49 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      5/9/25 11:23:18 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      5/7/25 9:53:18 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    Financials

    Live finance-specific insights

    See more
    • AstraZeneca's Q1 2025 Financial Results

      Growth momentum and pipeline delivery set AstraZeneca on a strong trajectory towards 2030 ambition AstraZeneca: Revenue and EPS summary   Q1 2025 % Change       $m Actual CER1       - Product Sales 12,875 6 9       - Alliance Revenue 639 40 42       Product Revenue2 13,514 7 10       Collaboration Revenue 74 64 64       Total Revenue 13,588 7 10       Reported EPS ($) 1.88 34 32       Core3 EPS ($) 2.49 21 21       Key performance elements for Q1 2025 (Growth numbers at constant exchange

      4/29/25 2:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance
    • AstraZeneca's Full Year and Q4 2024 results

      Strong momentum in FY 2024 with Total Revenue and Core EPS up 21% and 19% respectively AstraZeneca: Revenue and EPS summary     FY 2024 % Change Q4 2024 % Change $m Actual CERi $m Actual CER - Product Sales 50,938 16 19 13,362 18 19 - Alliance Revenue   2,212 55 55 714 68 69 - Collaboration Revenue 923 56 54 815 >2x >2x Total Revenue   54,073 18 21 14,891 24 25 Reported EPS $4.54 18 29

      2/6/25 7:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    Leadership Updates

    Live Leadership Updates

    See more
    • I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

      ROCKVILLE, Md., June 6, 2024  /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team. "I am pleased to welcome Dr. Phillip Dennis as our Chief Medical

      6/6/24 7:00:00 AM ET
      $AZN
      $IMAB
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alexion Canada Raises Awareness for Rare Diseases Through International colourUp4RARE Campaign

      In recognition of Rare Disease Day on February 29, Alexion welcomes people across the country to join the international colourUp4RARE challenge and learn more about the impact of rare diseases on an estimated three million Canadian families MISSISSAUGA, ON, Feb. 26, 2024 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, is marking Rare Disease Day on February 29 by launching colourUp4RARE. The international campaign aims to raise awareness of how to improve quality of life of people living with rare diseases in Canada, and around the world. Approximately,

      2/26/24 9:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

      NIH data show that globally less than 2% of genetic information being studied today originates from people of African ancestry1 The newly established Diaspora Human Genomics Institute (DHGI) will manage the Together for CHANGE initiative, which aims to increase available genomic data for people of African ancestry and enhance representation in STEM careers NASHVILLE, Tenn. and TARRYTOWN, N.Y. and WILMINGTON, Del. and BAGSVAERD, Denmark and BASEL, Switzerland, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Meharry Medical College, along with partners Regeneron Genetics Center® (RGC™), AstraZeneca, Novo Nordisk, and Roche, today announced the launch of the Together for CHANGE™ ("Changing Healthcare for

      10/18/23 9:00:00 AM ET
      $AZN
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by AstraZeneca PLC (Amendment)

      SC 13G/A - ASTRAZENECA PLC (0000901832) (Subject)

      2/4/22 9:06:48 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - ASTRAZENECA PLC (0000901832) (Subject)

      2/3/21 1:13:21 PM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care